NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal...
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from...
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess...
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings,...
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT)...
B. Riley Securities analyst Madison Elsaadi maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.74.Elevate Your Investing Strategy:...
In a report released today, Jay Olson from Oppenheimer upgraded Ovid Therapeutics to a Buy, with a price target of $7.00. The company’s shares closed yesterday at $1.58.Elevate Your Investing Strategy:...
Wedbush analyst Laura Chico maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.84.Elevate Your Investing Strategy: Take advantage...